Update on CD4+ T-Cell Counting Technologies

Similar documents
hiv/aids Diagnostics Technology Landscape october 2012

Outline. Role of POC CD4 in the conenuum of care. How does POC CD4 compare with Lab based tests. Issues of sampling: venous vs capillary sampling

Alere Technologies GmbH

WHO Prequalification of Diagnostics Programme PUBLIC REPORT Product: Pima CD4 Test Number: PQDx Abstract

hiv/aids Diagnostics Technology Landscape november 2013

PointCare NOW TM Technical Note

WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT. Product: Alere q HIV-1/2 Detect WHO reference number: PQDx

8 MINUTES TO BETTER HIV/AIDS PATIENT CARE

Acceptability and feasibility of point-of-care CD4 testing on HIV continuum of care in low and middle income countries: a systematic review

HIV/AIDS DIAGNOSTICS TECHNOLOGY LANDSCAPE SEMI- ANNUAL UPDATE. January 2015

WHO Prequalification of Diagnostics Programme PUBLIC REPORT

HIV immunological and virological monitoring tools. Pascale Ondoa 5th INTEREST workshop Dar es Salam Thursday 12th, 2011

INNOVATIVE HIV POINT-OF CARE (POC) CD4, EARLY INFANT DIAGNOSIS (EID) AND VIRAL LOAD (VL) TECHNOLOGIES

Forum for Collaborative HIV Research External Validation of CD4 and Viral Load Assays Paris, France June 29, 2007

How can Blood Stabilizers be used for Validation of New Instruments? UK NEQAS for Leucocyte Immunophenotyping

Rapid Diagnostics CHAI Experience. 6 th Moving Forward in Diagnostics Forum Les Pensieres November 7, 2012

POINT OF CARE DIAGNOSTICS

CD4 Assays Are No Longer Needed for Care of Children in Low-resource Countries. The case against Di Gibb

WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT. Product: OraQuick HCV Rapid Antibody Test Kit WHO reference number: PQDx

Draft Report WHO evaluation of HIV 1/2 STAT-PAK (Chembio Diagnostic Systems Inc)

External validation for CD4 and viral load assays: South African Experience

Performance of point-of-care CD4 testing technologies in resource-constrained settings: a systematic review and metaanalysis

Digital Microscopy and Diagnosis on Cellphones

THE AVAILABILITY AND USE OF HIV DIAGNOSTICS: A 2012/2013 WHO SURVEY IN LOW-AND MIDDLE-INCOME COUNTRIES TECHNICAL REPORT

CD4 Counting in Mozambique s

Technical Brief on CD4 Technologies (May 2010)

Balancing investment in point of care diagnostics versus laboratory testing in low resource settings. June 28, 2011

Performance Characteristics of the Daktari CD4 System

QASI perspective on POC EQA

WHO Prequalification of Diagnostics Programme PUBLIC REPORT. Product: INSTI HIV-1/HIV-2 Antibody Test Number: PQDx

Review Article Point of Care Technologies for HIV

WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT. Product: DPP HIV 1/2 Assay WHO reference number: PQDx

Utility of the point of care CD4 analyzer, PIMA, to enumerate CD4 counts in the field settings in India

WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT. Product: Alere HIV Combo WHO reference number: PQDx

Point-of Care Technology:

PEPFAR and Treatment 2.0

CyFlow Counter. The Complete Solution for HIV/AIDS Monitoring. Essential Healthcare. HIV/AIDS Monitoring Patient Follow-up

ACS GUIDELINE FOR LYMPHOCYTE SUBSET IMMUNOPHENOTYPING. Second Edition Australasian Cytometry Society Guideline Document

Microfluidics and Biosensors for Point-of- Care Diagnostics

East Africa Regional CD4 Workshop: The Role of CD4 Testing During Viral Load Scale-Up

Microfluidic Devices for Point-of-Care Diagnostics Xuanhong Cheng

WHO Prequalification of Diagnostics Programme PUBLIC REPORT. Product: HIV 1/2 STAT-PAK Number: PQDx Abstract

BD CBA on the BD Accuri C6: Bringing Multiplexed Cytokine Detection to the Benchtop

The Laboratories Role in Global Health

Diagnostics: Bench to Bedside Pathway

CrAg Lateral Flow Assay Standard Operating Procedure

CD4 WORKSHOP REPORT JULY 22, 2017

Polymer Technology Systems, Inc. CardioChek PA Comparison Study

WHO Prequalification of Diagnostics Programme PUBLIC REPORT

Microfluidic Devices for HIV Point-of-Care Diagnostics Xuanhong Cheng

WHO Prequalification of In Vitro Diagnostics Programme PUBLIC REPORT. Product: First Response HIV Card Test Number: PQDx

Abbott Cell-Dyn Reticulocyte Method Comparison and Reticulocyte Normal Reference Range Evaluation

WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT. Product: OraQuick HIV 1/2 Rapid Antibody Test WHO reference number: PQDx

WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT. Product: OraQuick HIV 1/2 Rapid Antibody Test WHO reference number: PQDx

Laboratory Strengthening Gloria Young BD Biosciences

QASI QUALITY ASSESSMENT AND STANDARDIZATION OF IMMUNOLOGICAL MEASURES FOR HIV/AIDS

Scaling Up Routine Viral Load in Resource Limited Settings. MSF experience in Zimbabwe

Global Trends in Early Infant Diagnosis of HIV

TAP HERE TO SEE THE PRODUCT

ICASA SATELLITE SYMPOSIUM Tuesday, 1 December 18:30 20:30 Prof. Soudre Room Rainbow Towers Conference Centre. Twitter Hash Tag: #EIDInnovation

EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva, 29 October to 2 November 2018

Microchip Technology. Xuanhong Cheng Materials Science and Engineering

Application Information Bulletin: Navios Multi-center Study

WHO Prequalification of In Vitro Diagnostics Programme PUBLIC REPORT. Product: Uni-Gold HIV Number: PQDx Abstract

CEPHIA Consortium for the Evaluation and Performance of HIV Incidence Assays STANDARD OPERATING PROCEDURE

Bio-Rad Laboratories. Hemoglobin Testing. VARIANT II Hemoglobin Testing System For HbA 1c

DIAGNOSTICS AND THERAPEUTICS FOR HIV: GLOBAL MARKETS

SHORT, MEDIUM AND LONGER TERM PRODUCT DEVELOPMENT PRIORITIES IN HIV-RELATED DIAGNOSTICS WHO EXPERT MEETING REPORT ON 6 7 JUNE 2012 GENEVA, SWITZERLAND

Received 6 November 2006/Returned for modification 4 January 2007/Accepted 9 January 2007

MARSHALLTOWN MEDICAL & SURGICAL CENTER Marshalltown, Iowa

Mission Hb accurately detects both

Step-by-Step Instructions For OraQuick HCV Rapid Antibody Test

FinTest IgG4 Screen 20 ELISA KIT

Alere q A Molecular Platform for Global Health Diagnostics

Evaluation of Dried Blood Spots (DBS) for Human Immunodeficiency Virus (HIV-1) Drug Resistance Testing

WHO Prequalification of In Vitro Diagnostics Programme PUBLIC REPORT. Product: Uni-Gold HIV Number: PQDx Abstract

Testing for G6PD deficiency for safe use of primaquine in radical cure of P. vivax and P. ovale

In Vitro Diagnostic Platforms for the Developing World. David Kelso Oak Ridge April 20, 2012

Performance evaluation of Celltac G: a new automated hematology analyzer

Introduction to PAHWP-EAC-LSHTM Workshop on Assessment of Clinical Performance of in-vitro Diagnostics

PanLeucogating Akin Abayomi

DETERMINE SPECIMEN REQUIREMENTS HIV-1/2 Ag/Ab Combo TESTING PROCEDURE

Rapid Point-of-Care Tests for STIs: needs, progress, challenges

BD Multitest IMK Kit

Target Product Profile: Point-of-Care Malaria Plasmodium falciparum Highly Sensitive Rapid Diagnostic Test

Surge plan, current capacities & challenges reaching full capacity Dr Sergio Carmona

PUTTING HIV AND HCV TO THE TEST A PRODUCT GUIDE FOR POINT-OF-CARE CD4 AND LABORATORY-BASED AND POINT-OF-CARE VIROLOGICAL HIV AND HCV TESTS

CyFlow SL_3. Healthcare Immunology. Portable FCM System for Routine HIV/AIDS Monitoring of Adult and Pediatric Patients

SP.718 Special Topics at Edgerton Center: D-Lab Health: Medical Technologies for the Developing World

Funding Universal Access through a Global Health Charge on alcohol and tobacco: feasibility in the 20 countries with the largest HIV epidemics

Why do we need SD LipidoCare?

Alere INRatio 2 METHOD AND SAMPLE COLLECTION

Hepatitis C Virus (HCV) Antibody Test

Rotavirus Test Kit. Instructions For Use. Format: Cassette Specimen: Fecal Extract Catalog Number: VEL-001-ROTA

PROCEDURE NO. POC LBH. Printed copies are for reference only. Please refer to the electronic copy for the latest version.

New Generation of Nucleic Acid Testing. Michele Owen, Ph.D Division of HIV/AIDS Prevention Centers for Disease Control & Prevention

UNITAID investments to innovate and scale up access to HIV diagnostics

Improving Access to Healthcare in the Developing World. Renuka Gadde VP, Global Health 21 October 2012

Technical Bulletin No. 157

Point of Care (POC) diagnostics for microbial infections and POC susceptibility measurements: The need in Indian context. Dr.

Transcription:

Update on CD4+ T-Cell Counting Technologies Thomas Denny, MSc, M.Phil Professor of Medicine Duke Human Vaccine Institute Duke University Medical School UK NEQAS 24 th June 2013, Sheffield

2

3

4

5

6

Levels of Clinical Care and Laboratory Services Central Level Regional Referral Centers District Hospital Level 7 Primary Health Care Level

From 3 x 5 to Universal Access Globally that means 10 million plus on ART by 2010 8 Limited or no stable Electricity, poor water supply, poor facilities + Electricity + Water + Facility 4-5 hours Travel Time 4-5 hours

9 Clinical Need for POC CD4 Technologies WHO recommends ART for HIV+ people with CD4 counts of 350 cells/mm3 (2010 revision)

10 CD4 Enumeration Technologies Available

11 Alere PIMA CD4 Absolute CD4 enumeration using a small, portable reader Read based on static image; not flow cytometrybased Sample Loading: 25µL capillary or fingerstick whole blood applied directly to cartridge Time to result: 20 minutes Key Features: No manual sample handling or processing Dried reagents sealed in disposable cartridge No refrigeration necessary Current Status: Available

12 Evaluations of Alere PIMA CD4 10 peer-reviewed evaluations have been published 1790 participants; 21 ART centers in India (Thakar M, 2012) Compared PIMA with reference Flow Cytometry-based methods Could identify patients eligible for ART in 91% of cases 254 participants; London adult HIV outpatient service (Herbert, A, 2012) The laboratory and POCT results were strongly correlated, r=0.93 (p<0.001), but were generally lower for the POCT Sensitivity: 95%; Specificity: 88% 206 participants; ID clinical in Kampala, Uganda (Manabe YC, 2012) Fingerstick PIMA had a mean bias of 66.3 cells/µl Bias smaller in lower CD4 counts (0 250 cells/µl; bias -10.8) and much greater in higher CD4 counts (>500 cells/µl; bias -120.6) Multiple studies have shown reduced correlation with fingerstick compared to venous blood collection (Glencross, DK, 2012; Diaw, PA, 2011; Thakar M, 2012) Training is necessary for finger prick sample collection

13 Comparison of Fingerstick with Venipuncture Previously IQA compared fingerstick with venipuncture 30 donors with blood collected using both methods All samples run on FACSCalibur No observed bias with fingerstick method Data from Wong, J and Louzau, R

14 Fingerstick Collection Evaluation Small study to assess blood volume collect from fingerstick BD lancets (2mm) primary; Unistick lancets (3 mm) secondary 29/30 (96.7%) successful fingersticks All successful fingersticks used 2 mm lancet 1 fingerstick unsuccessful with either 2 or 3 mm lancet Microclots observed during 1 st round of collection; with additional practice only 1 microclot was observed Average fingerstick volume ~260 µl; range 150-400 µl Data from Kelly Seaton

15 Partec CyFlow minipoc CD4 # and CD4% enumerations using advanced laser optics and microfluidics Sample Loading: Mix 20µL EDTA blood to dry mab tube Time to results: Analysis requires 40-70 seconds Throughput: 250 tests per day Key Features: Affordable dry/lyophilized mab reagents with a 6 month shelf-life Can run on power supply, rechargeable battery pack or solar panels Current Status: Available

16 Evaluations of Partec CyFlow minipoc No peer-reviewed published evaluations Preliminary data from NMRL Zimbabwe Source: http://partec.com

17 HumaCountCD4 NOW (Formerly PointCare Now) CD4/CD4% Hematology System Measures 12 parameters (WBC, HGB, % and # LYM, NEU, MON, EOS, CD4) Sample Loading: Whole blood from venipuncture Time to Results: 8 minutes Throughput: ~40-50 samples per day Key Features No manual preparation steps closed-tube system Heat stable (20-30ºC) reagents Automated gating Current Status: Available

18 Evaluation of HumaCountCD4 Bergeron, M, et al. evaluated system (when PointCareNOW) in 2012 Five independent evaluations in South Africa and Canada Total of 492 blood samples evaluated with PointCareNow and reference flow cytometry instruments PointCareNow significantly overestimated CD4 counts with a mean relative bias of +35% Could identify patients eligible for ART only 47% of cases Unclear what changes if any made with HumaCountCD4

19 CD4 Enumeration Technologies in Development

20 Visitect CD4 (Burnet and Omega Diagnostics Ltd.) Lateral flow technology that measures CD4 proteins compared to a control line representing 350 CD4/ μl Sample loading: Finger-prick of whole blood applied to disposable cartridge Time to results: Provides semi-quantitative (treat vs. no treat) results in 40 minutes Throughput: ~120 samples per technician per day Cost: ~$5.00/test Key Features: Visual result interpretation Optional reader that provides non-subjective result interpretation, full traceability, and data storage 97% sensitivity for samples below 350 CD4/μL 80% specificity for samples about 350 CD4/μL Current Status: Projected Available Late 2013

21 Evaluations of Visitect CD4 No peer-reviewed published evaluations Preliminary data from Alfred Hospital, Melbourne, Australia Source: http://www.omegadiagnostics.com/cd4/

22 Zyomyx CD4 test (Zyomyx, Inc.) Utilizes CD4-specific cell stacking approach (measurement of length as a function of CD4 cell count) Sample Loading: Finger-prick applied to cartridge Time to Results: Less than 10 minutes from patient to result Cost: Less than $10.00 per test Key Features No electricity or battery required Only 2.5 in length Equivalent results to flow cytometry Current Status: In development

23 Evaluations of Zyomyx No peer-reviewed publications Data from Zyomyx shows strong correlation with Flow Cytometry Source: http://www.zyomyx.com

24 Daktari TM CD4 Counter (Daktari Diagnostics, Inc.) Small, portable device that utilizes microfluidic-based cartridges to selectively capture CD4 cells Sample Loading: Blood from finger-stick is applied directly to cartridge Time to Results: ~10 minutes Throughput: ~40-50 samples a day Anticipated Cost: ~$8.00 per test Key Features Absolute CD4 counts are measured via electrochemical sensing (no lasers) No manual sample preparation is required Current Status: In development and undergoing performance evaluation

25 Evaluations of Daktari TM CD4 Counter No independent validation Field-testing in Kenya scheduled for summer 2013 Cheng, X, et al., 2007 evaluated prototype system Evaluated 49 HIV-positive subjects Close correlation with Flow Cytometry <200 cells/ul= 0.86 <350 cells/ul=0.90 <500 cells/ul=0.97

26 MBio CD4 system (MBio Diagnostics Inc.) Two color fluorescence imaging cytometer Determines absolute CD4 counts based on immunostaining and direct cell counting Sample Loading: Fingerstick or venous whole blood samples applied to a single-use disposable cartridge Time to Results: ~25 minutes 20 minute incubation period and 3.5 minutes for reader processing Throughput: ~10-15 samples per hour Key Features: The CD4 cell-counting system consists of a reader and single-use disposable cartridges Future versions will be capable of determining CD4/CD8 ratio, CD4% and hemoglobin Samples can be processed in parallel utilizing a separate cartridge rack with automatic timing Current Status: Currently undergoing field testing CD4+ cell counts for both capillary and venous whole blood samples are comparable to those established using flow cytometry methods

27 Evaluations of MBio CD4 system Mbio in collaboration with University of California, San Diego evaluated prototype device (Logan, C, et al., 2013) 94 venipuncture and 52 capillary samples were analyzed with both Mbio and Flow Cytometry Both showed minimal bias Venipuncture mean bias of -10 cells/µl Capillary Samples mean bias of -4 cells/µl Higher variability with capillary samples vs. venipuncture Using a treatment threshold of 350 cells/µl, fingerstick misclassified two as no treat

28 BD FACSPresto TM (BD Biosciences) Small, bench-top, fixed volume cytometer Sample loading: blood applied directly to cartridge Time to result: ~25 minutes 20 minute incubation of cartridge, 2-5 minute acquisition Throughput: 25-30 samples per day Key Features: Measures absolute CD4, CD4% and hemoglobin Current Status: Expected to launch in late 2013 No evaluations reported by BD or published

29

30 Quality Control / Assessment Internal SOPs Staff Training Reference Ranges Assay Controls External IQA UK NEQAS CAP SA NHLS QASI

31 Recommendations to Assess New Technology A validation plan should be developed in collaboration with a statistician New technology should be compared to flow cytometry as the Gold Standard methodology Donors with a range of CD4 counts should be tested Samples should be blinded to operating technician Matched samples should be tested at more than one testing site, when possible Each site should run Flow Cytometry and New Technology Testing sites should participate in External Flow Cytometry QC program(s)

32 Sources UNITAID HIV/AIDS Diagnostic Technology Landscape Semi- Annual Update (Oct. 2012) http://www.omegadiagnostics.com/cd4/ http://www.daktaridx.com/products/ http://mbiodx.com/products/ http://www.retroconference.org/2012b/pdfs/686.pdf http://www.zyomyx.com/ https://workspace.imperial.ac.uk/cd4/public/zyomyx%20cd4% 20Open%20Day.pdf http://pimatest.com/en/pima-platform/pima-cd4.html http://www.partec.com/ http://www.human.de/en/products/hematology/instruments-andsystems/cell-counter.php

33 UNITAID RFA 2013 HIV Monitoring Technologies and Early Infant diagnosis African Evaluation sites Rosanna Peeling London School of Hygiene and Tropical Health

34